The Goldman Sachs Group Lowers Esperion Therapeutics (NASDAQ:ESPR) Price Target to $3.00

Esperion Therapeutics (NASDAQ:ESPR) had its target price lowered by equities research analysts at The Goldman Sachs Group from $4.00 to $3.00 in a research note issued on Thursday,Benzinga reports. The brokerage currently has a “neutral” rating on the biopharmaceutical company’s stock. The Goldman Sachs Group’s price objective points to a potential upside of 211.85% from the stock’s previous close.

A number of other research analysts have also commented on ESPR. Needham & Company LLC reissued a “buy” rating and set a $5.00 price target on shares of Esperion Therapeutics in a report on Tuesday, April 8th. JMP Securities reissued a “market outperform” rating and set a $4.00 price objective (down from $7.00) on shares of Esperion Therapeutics in a research note on Tuesday, February 11th. Finally, HC Wainwright reissued a “buy” rating and issued a $16.00 target price on shares of Esperion Therapeutics in a research report on Thursday, March 20th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, Esperion Therapeutics has an average rating of “Hold” and an average price target of $6.42.

Esperion Therapeutics Trading Down 0.2 %

Esperion Therapeutics stock traded down $0.00 during midday trading on Thursday, reaching $0.96. 2,742,666 shares of the stock traded hands, compared to its average volume of 5,651,431. The firm has a fifty day moving average price of $1.53 and a two-hundred day moving average price of $2.00. Esperion Therapeutics has a fifty-two week low of $0.93 and a fifty-two week high of $3.94. The firm has a market cap of $190.33 million, a price-to-earnings ratio of -1.50 and a beta of 0.86.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. Mackenzie Financial Corp grew its position in shares of Esperion Therapeutics by 116.1% in the fourth quarter. Mackenzie Financial Corp now owns 143,252 shares of the biopharmaceutical company’s stock valued at $315,000 after purchasing an additional 76,965 shares during the last quarter. Two Sigma Advisers LP increased its position in Esperion Therapeutics by 0.4% in the 4th quarter. Two Sigma Advisers LP now owns 3,616,200 shares of the biopharmaceutical company’s stock worth $7,956,000 after buying an additional 16,100 shares during the period. Rafferty Asset Management LLC acquired a new position in shares of Esperion Therapeutics during the fourth quarter worth approximately $82,000. ProShare Advisors LLC boosted its position in shares of Esperion Therapeutics by 75.2% in the fourth quarter. ProShare Advisors LLC now owns 62,549 shares of the biopharmaceutical company’s stock valued at $138,000 after acquiring an additional 26,843 shares during the period. Finally, Nuveen Asset Management LLC grew its stake in shares of Esperion Therapeutics by 48.6% in the fourth quarter. Nuveen Asset Management LLC now owns 3,119,253 shares of the biopharmaceutical company’s stock worth $6,862,000 after acquiring an additional 1,020,243 shares during the last quarter. Institutional investors own 47.39% of the company’s stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.